Clinical Trials Browser

Has announcements × Neoplasm Metastasis × Clear all

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT04886804 2026-03-13

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1 Active not recruiting

608 enrolled 5 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 2 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

270 enrolled 3 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 1/2 Active not recruiting

731 enrolled 3 FDA

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 3 FDA

Neoplasm Metastasis

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 5 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis